Silence Therapeutics wants to list on Nasdaq while pursuing new deals; Surface Oncology inks latest Keytruda collaboration
→ Surface Oncology $SURF has joined the long lineup of biotechs to match one of their drugs with Merck’s powerhouse franchise therapy Keytruda. The biotech will collaborate with Merck on combining Surface’s CD39-targeted SRF617 with the checkpoint in a Phase I/Ib in solid tumors.
→ Silence Therapeutics — listed in London as $SLN — is jumping the Atlantic to Nasdaq. The biotech struck a deal with AstraZeneca recently, and now wants to add to its list of collaborations. In a statement today, the company noted: “Following the recent announcement of the multi-target AstraZeneca collaboration in March, the Company continues to hold discussions with a number of third parties regarding possible partnership and collaboration opportunities. Accordingly, the Company is strengthening its Business and Alliance Management capability under the leadership of John Strafford, VP, Business Development, with a view to accommodating an expansion of its existing third-party relationships and, as appropriate, additional collaborations.”